Sanjay P. Bagaria, M.D., uses next-generation sequencing technology to study the tumor and tumor microenvironment of sarcoma, peritoneal surface malignancies and melanoma. The long-term goal of Dr. Bagaria's research is to develop locoregional therapies that can prevent and eradicate these tumors.
Dr. Bagaria's research team has conducted extensive research using preclinical models and advanced genomic sequencing techniques to better identify immune and targeted therapeutics for advanced malignancies.
- Developing novel therapies to treat peritoneal surface malignancies. Peritoneal metastasis is poorly understood and fatal. Dr. Bagaria's team studies novel therapies that combine surgical debulking with a variety of immune and targeted agents to better treat this disease.
- Understanding the molecular factors that result in local recurrence following resection of sarcomas. Retroperitoneal sarcomas have a local recurrence rate of over 50 percent. Little is known about the molecular characteristics that predict recurrence. Dr. Bagaria's team utilizes a variety of next-generation sequencing technologies that aim to identify these factors with the hope that the findings will lead to new treatment options.
- Combining surgical resection and immunotherapy in the treatment of metastatic melanoma. New developments in immunotherapy have revolutionized the treatment of metastatic melanoma. Dr. Bagaria's research team studies the genomic variables that predict response to surgical resection following immunotherapy.
Significance to patient care
Advances in genomic sequencing technology now make it possible to integrate genomic data into the clinical practice. However, how best to do this is still unclear. Dr. Bagaria hopes that through his research clinicians can individualize treatment for patients with advanced malignancies based on the genomic characterization of the tumor and tumor microenvironment.
- Director, Center for Individualized Medicine, Mayo Clinic in Jacksonville, Florida, 2018-present